Diabetes mellitus (DM) is a growing epidemic that is causing a significant socioeconomic burden on nations throughout the world. Among all causes of death, obesity ranks fifth globally. The term "twin epidemics" refers to the growing global issue of obesity and diabetes prevalence, particularly in wealthy nations29. Adopting healthy behaviours is a challenge for those who suffer from obesity, an illness related to lifestyle. Behavioural and lifestyle variables, such as poor sleep hygiene, bad eating habits, sedentary lifestyles, being overweight, and socioeconomic status, are some examples of modifiable risk factors for obesity. Nonetheless, genetics, macrosomia at birth, gender, ethnicity, and age are non-modifiable risk factors for obesity8. Since the standard treatment approaches have serious side effects and have not addressed the disease's underlying causes, new solutions for managing diabetes mellitus are emerging quickly14. Therefore, cutting-edge therapeutic strategies are required. Known as a "twincretin," tirzepatide is the only dual agonist of the glucagon-likepeptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) receptors that is considered a "first-in-class" medication. It can significantly lower blood sugar levels and enhance insulin sensitivity, as well as improve lipid metabolism and reduce body weight by more than 20% 29. This article outlines essential features of the SURPASS and SURMOUNT trials. It also summarizes the current clinical study program and the respective outcomes and highlights further potential indications for tirzepatide in the treatment of obesity. It emphasizes the as the need for further research to guide future clinical practice.